They Said Pfizer Never Cured Anything And I Beg To Differ

They may have said it, but history has receipts…

Source: Total Assignment Help (Pinterest)

In recent times, social media has been flooded with posts suggesting that pharmaceutical companies deliberately avoid discovering cures because they profit more from lifelong treatments. Like one of them I saw, claiming that Pfizer has never cured any disease. Funnily enough, they may sound convincing at first, but a closer look at reality shows a more complex story. While there is a tension between profit motives and public good in the pharmaceutical industry, it is misleading and factually wrong to conclude that companies like Pfizer have never contributed to genuine cures or that they intentionally suppress them.

We should all know that chronic diseases require continuous treatment, creating recurring revenue for drug manufacturers, whereas a one-time cure eliminates repeat sales. In a world where pharmaceutical research is expensive, risky, and profit-driven, it’s easy for the public to suspect that companies prefer treatments over cures. This narrative is emotionally powerful, especially in societies where drug prices are high, access to healthcare is unequal, and patients feel exploited by corporate interests.

But the truth is not as black and white. While economic incentives do influence research priorities, the claim that pharmaceutical firms never create cures is false. In fact, the history of medicine shows that industry-driven discoveries have saved millions of lives by eradicating or curing diseases that were once fatal.

Pfizer, one of the largest and most criticized pharmaceutical companies today, has a long history of producing life-saving drugs. During World War II, Pfizer revolutionized the production of penicillin, the first true antibiotic that could cure bacterial infections. Before penicillin, a simple cut or pneumonia could be a death sentence. Pfizer’s deep-tank fermentation process allowed mass production of penicillin, making it widely available to allied soldiers and later civilians. That achievement alone qualifies as one of the greatest medical breakthroughs in history and it was a cure.

Beyond penicillin, Pfizer’s innovations have continued to shape public health. The company developed antibiotics such as Terramycin (oxytetracycline) and antifungal agents like Diflucan (fluconazole), which have cured countless infections worldwide. More recently, Pfizer collaborated with BioNTech to produce one of the first mRNA COVID-19 vaccines, a preventive tool that drastically reduced hospitalizations and deaths. Though vaccines prevent rather than cure diseases, their impact on saving lives is undeniable in preventing infection, in many ways, the best kind of cure.

Hence, the blanket claim that Pfizer has never cured any disease is factually inaccurate. While no company is free from profit motives or controversy, Pfizer’s history clearly shows contributions to genuine cures and preventive medical advances.

Why do people still believe that pharmaceutical companies avoid cures?

So the answer lies partly in the structure of pharmaceutical economics. Developing a new drug can cost over a billion dollars and take more than a decade. Chronic diseases such as diabetes, hypertension, and arthritis offer companies predictable, long-term markets. In contrary, a one-time cure for a disease like hepatitis C, while groundbreaking, can limit long-term revenue once the affected population is treated.

For instance, Gilead Sciences’ hepatitis C cure, Sovaldi, which achieved cure rates of over 90%. However, the initial price around $84,000 per course stirred outrage and led to restricted access in many countries. This shows how market forces and pricing decisions can make even a life-saving cure inaccessible to those who need it most, reinforcing the public belief that cures are intentionally kept out of reach.

Still, it’s critical to understand that science and incentives are different from conspiracy. Most researchers, including those in big pharmaceutical firms, genuinely aim to solve health problems. The bottleneck is not the lack of will to cure but rather how the global health system rewards or funds innovation.

The Real Problem

The main issue is on how pharmaceutical incentives are structured. Current systems reward companies for what sells, not necessarily for what saves lives. Chronic medications ensure steady revenue, while cures may be less attractive from a purely financial standpoint. Yet this doesn’t mean companies deliberately hide cures rather, they invest more in areas where profit and demand are stable.

Moreover, scientific reality plays a role. Many diseases including cancers, Alzheimer’s, and autoimmune disorders are extraordinarily complex and difficult to cure. Developing permanent solutions is not just expensive; it’s often scientifically elusive.

This is why public-private partnerships, government funding, and non-profit research are vital. They help fill gaps where private profit alone can’t justify the risk or expense of developing a cure.

The Way Forward

If the “cure eliminates customers” problem indicates uneven incentives, then the solution is to realign them. Here’s how I believe it could be done:

• Advance Market Commitments and Prizes: Governments and donors can guarantee financial rewards for developing cures for high-priority diseases. This reduces the financial risk for companies and encourages innovation.
• Value-Based and Outcome-Based Pricing: Health systems can pay for drugs based on how well they work, spreading costs over time rather than paying everything upfront for one-time cures.
• Open Science and Patent Pooling: Encouraging voluntary licensing and open research for diseases of global importance ensures that breakthroughs benefit everyone, not just wealthy nations.
• Public Investment in Early Research: Since the private sector often focuses on profitable areas, governments can fund the early, risky stages of cure-focused research.

Correcting the Record and Changing the Narrative

It is true that the pharmaceutical industry operates within a profit-driven system, and sometimes that system delays or distorts public access to cures. However, saying that Pfizer has never cured any disease is historically false and dismisses decades of genuine scientific contributions.

The issue here is not that Big Pharma hides cures, but that the world hasn’t yet built a system that rewards curing diseases as much as it rewards treating them. Fixing that imbalance is the real challenge.

The story shouldn’t end with hopeless cynicism or blind outrage. It should end with accountability, transparency, and reform. Pharmaceutical innovation has given humanity antibiotics, vaccines, and now gene therapies which are remarkable tools that have cured or prevented countless diseases. But innovation alone isn’t enough. Governments, scientists, and citizens must work together to ensure that medical breakthroughs serve public health first and profit second.